Pangaea Oncology (XMAD:PANG) Moat Score: 0/10 (As of Jul. 13, 2026)


XMAD:PANG Pangaea Oncology SA XMAD:PANG
60 GF Score
Price €1.57
GF Value €2.16
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology Moat Score?

Pangaea Oncology has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Pangaea Oncology has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pangaea Oncology might have No Moat - No discernible moat.

Pangaea Oncology  (XMAD:PANG) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pangaea Oncology Moat Score Related Terms

XMAD:PANG
60GF Score
Pangaea Oncology SA XMAD:PANG
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.57 is trading 27.3% below its estimated GF Value™ of €2.16. GuruFocus considers Pangaea Oncology to be Modestly Undervalued.

Key valuation signals for XMAD:PANG:

  • Moat Score: 0
  • GF Value™: €2.16 vs. price of €1.57 (27.3% below fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
60GF Score

Get the complete analysis for XMAD:PANG

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.57
Price
€2.16
GF Value